Seroconversion and duration of immunity after vaccination against group C meningococcal infection in young children-Reference-Cited by-同舟云学术

Seroconversion and duration of immunity after vaccination against group C meningococcal infection in young children

Published:2000-06 Issue:24 Volume:18 Page:2656-2660
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Espı́n Rı́os Isabel,Garcı́a-Fulgueı́ras Ana,Navarro Alonso José A,Vazquez Moreno Julio,Rodriguez Gonzalez Tomás,Navarro Sánchez Carmen,Pérez-Flores Domingo

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference26 articles.

1. Comentario Epidemiológico de las enfermedades de declaración obligatoria (EDO) y sistema de información microbiológica (SIM). España. Año 1996. Bol Epidemiol Semanal 1997;5(1):4.

2. Dirección General de Salud. Enfermedad meningocócica en la Región de Murcia: Temporada epidemiológica 1996–1997. Boletı́n Epidemiológico de Murcia 1997;19:5–12.

3. Kinetics of antibody production to group A and group C meningococcal vaccines administered during the first six years of life: prospect for routine immunization on infants and chidren;Gold;J. Infect. Dis.,1979

4. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children;Lepow;J. Infect. Dis.,1986

5. Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine;Maslanka;Infect. Immun.,1998

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Should we vaccinate the better seroconverters or the most vulnerable? Game changing insights for COVID-19 vaccine prioritization policies;Egyptian Pediatric Association Gazette;2021-12

2. Progress toward the global control ofNeisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development;Human Vaccines & Immunotherapeutics;2018-05-04

3. Prevalence of meningococcal meningitis in China from 2005 to 2010;Vaccine;2015-02

4. The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative;Expert Review of Vaccines;2013-08

5. Meningococcal vaccines;Vaccines;2013